Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 123876, 9 pages
http://dx.doi.org/10.1155/2015/123876
Research Article

Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry—The EXCITING-ILD Registry

1Pneumology and Respiratory Critical Care Medicine, Centre for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, 69126 Heidelberg, Germany
2Translational Lung Research Centre Heidelberg (TLRCH), Member of the German Centre for Lung Research (DZL), 69120 Heidelberg, Germany
3Institute of Health Economics and Healthcare Management, Helmholtz Centre Munich GmbH, German Research Centre for Environmental Health, Member of the German Centre for Lung Research (DZL), Comprehensive Pneumology Centre Munich (CPCM), 85764 Neuherberg, Germany
4Institute of Health Economics and Healthcare Management, Munich Centre of Health Sciences, Ludwig Maximilian University of Munich, 80336 Munich, Germany
5Association of German Pneumologists (BdP), 86150 Augsburg, Germany
6Medical Clinic II, University of Regensburg and Klinikum Donaustauf, 93093 Donaustauf, Germany
7Institute of Lung Research, 10405 Berlin, Germany
8Medical Clinic V, University Clinic, Ludwig-Maximilians-University Munich, Comprehensive Pneumology Centre Munich (CPC-M), Member of the German Centre for Lung Research (DZL), 81377 München, Germany
9Patient Support Group Lungenfibrose e.V., 45242 Essen, Germany
10Department of Translational Pulmonology, University of Heidelberg, 69120 Heidelberg, Germany
11Division of Paediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Paediatrics III, University of Heidelberg, 69120 Heidelberg, Germany
12Medical Clinic II, University Hospital Giessen, Universities of Giessen and Marburg Lung Centre (UGMLC), Member of the German Centre for Lung Research (DZL), 35392 Giessen, Germany
13Medical Clinic V (Pneumology), Cardiothoracic Centre, Campus Fulda, University Medicine Marburg, 36043 Fulda, Germany

Received 28 August 2015; Accepted 12 October 2015

Academic Editor: Paolo Spagnolo

Copyright © 2015 Michael Kreuter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Valeyre, B. Duchemann, H. Nunes, Y. Uzunhan, and I. Annesi-Maesano, “Interstitial lung diseases,” in Respiratory Epidemiology, T. Welte, I. Annesi-Maesano, G. Viegi, and B. Lundbäck, Eds., vol. 65 of ERS Monograph, chapter 6, ERS, 2014. View at Publisher · View at Google Scholar
  2. American Thoracic Society and European Respiratory Society, “American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 2, pp. 277–304, 2002. View at Publisher · View at Google Scholar
  3. W. D. Travis, U. Costabel, and D. M. Hansell, “An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 6, pp. 733–748, 2013. View at Publisher · View at Google Scholar
  4. GBD 2013 Mortality and Causes of Death Collaborators, “Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013,” The Lancet, vol. 385, no. 9963, pp. 117–171, 2015. View at Publisher · View at Google Scholar
  5. G. Raghu, H. R. Collard, J. J. Egan et al., “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. Swigris, A. L. Olson, T. J. Huie et al., “Sarcoidosis-related mortality in the United States from 1988 to 2007,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 11, pp. 1524–1530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. D. B. Coultas, R. E. Zumwalt, W. C. Black, and R. E. Sobonya, “The epidemiology of interstitial lung diseases,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 4, pp. 967–972, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Karakatsani, D. Papakosta, A. Rapti et al., “Epidemiology of interstitial lung diseases in Greece,” Respiratory Medicine, vol. 103, no. 8, pp. 1122–1129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Xaubet, J. Ancochea, F. Morell et al., “Report on the incidence of interstitial lung diseases in Spain,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 21, no. 1, pp. 64–70, 2004. View at Google Scholar · View at Scopus
  10. J. L. López-Campos and E. Rodríguez-Becerra, “Incidence of interstitial lung diseases in the south of Spain 1998–2000: the RENIA Study,” European Journal of Epidemiology, vol. 19, no. 2, pp. 155–161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Musellim, G. Okumus, E. Uzaslan et al., “Epidemiology and distribution of interstitial lung diseases in Turkey,” The Clinical Respiratory Journal, vol. 8, no. 1, pp. 55–62, 2014. View at Publisher · View at Google Scholar
  12. J. Gribbin, R. B. Hubbard, I. Le Jeune, C. J. P. Smith, J. West, and L. J. Tata, “Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK,” Thorax, vol. 61, no. 11, pp. 980–985, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. Kornum, S. Christensen, M. Grijota et al., “The incidence of interstitial lung disease 1995–2005: a Danish nationwide population-based study,” BMC Pulmonary Medicine, vol. 8, article 24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Demedts, A. U. Wells, J. M. Antó et al., “Interstitial lung diseases: an epidemiological overview,” The European Respiratory Journal, vol. 18, no. 32, supplement, 2001. View at Google Scholar
  15. M. Roelandt, M. Demedts, W. Callebaut et al., “Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992–1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding,” Acta Clinica Belgica, vol. 50, no. 5, pp. 260–268, 1995. View at Google Scholar · View at Scopus
  16. M. Thomeer, M. Demedts, and K. Vandeurzen, “Registration of interstitial lung diseases by 20 centres of respiratory medicine in flanders,” Acta Clinica Belgica, vol. 56, no. 3, pp. 163–172, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Schweisfurth, C. Kieslich, N. Satake et al., “How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases (‘fibrosis registry’) of the WATL,” Pneumologie, vol. 57, no. 7, pp. 373–382, 2003 (German). View at Publisher · View at Google Scholar · View at Scopus
  18. H. Schweisfurth, “Report by the Scientific Working Group for therapy of lung diseases: German fibrosis register with initial results,” Pneumologie, vol. 50, no. 12, pp. 899–901, 1996 (German). View at Google Scholar
  19. ERS, “Interstitial lung diseases,” in ERS European Lung Whitebook, chapter 22, ERS, 2015, http://www.erswhitebook.org/chapters/interstitial-lung-diseases/. View at Google Scholar
  20. J. Behr, M. Kreuter, M. H. Hoeper et al., “Management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry,” The European Respiratory Journal, vol. 46, no. 1, pp. 186–196, 2015. View at Publisher · View at Google Scholar
  21. L. Richeldi, R. M. du Bois, G. Raghu et al., “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2083–2092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. F. X. McCormack, Y. Inoue, J. Moss et al., “Efficacy and safety of sirolimus in lymphangioleiomyomatosis,” The New England Journal of Medicine, vol. 364, no. 17, pp. 1595–1606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Fioret, D. Mannino, and J. Roman, “In-hospital mortality and costs related to idiopathic pulmonary fibrosis between 1993 and 2008,” Chest, vol. 140, no. 4, Article ID 1038A, 2011. View at Publisher · View at Google Scholar
  25. E. Loveman, V. R. Copley, J. Colquitt et al., “The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation,” Health Technology Assessment, vol. 19, no. 20, pp. 1–336, 2015. View at Publisher · View at Google Scholar
  26. T. A. Workman, “Engaging patients in information sharing and data collection, the role of patient-powered registries and research networks,” Community Forum White Papers, American Institutes for Research, US Agency for Healthcare Research and Quality, Rockville, Md, USA, 2013. View at Google Scholar